Le Lézard
Classified in: Health, Science and technology, Business
Subjects: DIV, SHA

Spherix Issues Update to Shareholders Regarding Planned Dividend Distribution


NEW YORK, Sept. 25, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) President and CEO, Anthony Hayes, today released a letter to shareholders outlining the Company's plans for its previously disclosed dividend distribution.

Spherix Logo. (PRNewsFoto/Spherix Incorporated)

Dear Fellow Shareholders,

I want to thank all of you who recently voted to approve the Company's purchase of CBM BioPharma, Inc.'s assets. As previously stated, Spherix is moving forward with the distribution of 100,000 shares of common stock of Hoth Therapeutics, Inc. to its shareholders.

Spherix's Board of Directors will meet to set a record date for the stock dividend. Our shareholders who are owners of record on the record date will be paid the dividend distribution.  Shareholders who are not registered as of this date will not receive the dividend distribution.  Spherix's Board of Directors will also establish the ratio, which will designate how many shares of Hoth common stock each shareholder will receive for every share of Spherix stock owned by such shareholder.  Once this amount is set, Spherix will publicly announce this information, including the record date, and we will instruct Hoth's transfer agent to distribute the dividend distribution to the Spherix shareholders of record.

We understand the desire to receive the dividend and are working diligently to effectuate the dividend distribution. However, since we are issuing securities in another company, as opposed to cash, it is naturally a slower process. I want to assure each of our shareholders that we are working diligently on this matter and are moving as expeditiously as practicable to complete the dividend distribution.

Spherix continues to pursue additional strategic acquisitions to enhance shareholder value. Our recent press releases on the options we acquired from the University of Kentucky and the University of Maryland, Baltimore present exciting opportunities for the Company. Upon the closing of the CBM asset purchase, and following the dividend distribution, we will further update the market on the status of our other strategic acquisitions.

Thank you for being a shareholder of Spherix.

Sincerely,

Anthony Hayes

About Spherix
Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by active participation in the patent market. Spherix draws on portfolios of pioneering technology patents to partner with and support product innovation.

Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:


Investor Relations:

Hayden IR


Brett Mass, Managing Partner


Phone: (646) 536-7331


Email: [email protected]


www.haydenir.com



Spherix:

Phone: 212-745-1373


Email: [email protected]


www.spherix.com

 

SOURCE Spherix Incorporated


These press releases may also interest you

at 22:03
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 19:40
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

at 19:05
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

at 19:00
David J. Dykeman, co-chair of the Life Sciences & Medical...

at 18:30
Aspire Health Alliance ("Aspire Health") is a company headquartered in Braintree, Massachusetts, that provides behavioral health services in the community.  Aspire Health experienced a data security incident that may have involved personal and...



News published on and distributed by: